Wedbush downgraded Durata Therapeutics (NASDAQ: DRTX) from Outperform to Neutral with a price target of $13.00.

Analyst Gregory R ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE